Bokun, Jelena (6507641875)Jelena (6507641875)BokunGrujicic, Danica (7004438060)Danica (7004438060)GrujicicSkender-Gazibara, Milica (22836997600)Milica (22836997600)Skender-GazibaraParipovic, Lejla (55342754900)Lejla (55342754900)ParipovicPekmezovic, Tatjana (7003989932)Tatjana (7003989932)PekmezovicKisic-Tepavcevic, Darija (57218390033)Darija (57218390033)Kisic-TepavcevicIlic, Vesna (58717187600)Vesna (58717187600)IlicRaicevic, Savo (56176851100)Savo (56176851100)RaicevicStanic, Dragana (56941616400)Dragana (56941616400)StanicMiskovic, Ivana (57126111500)Ivana (57126111500)MiskovicSaric, Milan (19738345400)Milan (19738345400)SaricNikitovic, Marina (6602665617)Marina (6602665617)Nikitovic2025-07-022025-07-022018https://www.scopus.com/inward/record.uri?eid=2-s2.0-85054935605&partnerID=40&md5=d922367c93a277f021e70be72c3c8e13https://remedy.med.bg.ac.rs/handle/123456789/12938Purpose: The aim of this study was to present the management and treatment of children with medulloblastoma in Serbia, a middle-income country (MIC). Methods: The data of 87 children diagnosed with medulloblastoma and treated at the Institute for Oncology and Radiology of Serbia from 2000 to 2013 were analyzed. Results: The children’s median age was 8.3 years (range 2.5-17.3). Eighty-two (94.2%) were 3 years or older. Sixty-two (71.3%) patients had stage M0 medulloblastoma, 12 (13.8%) had stage M1 and 13 (14.9%) had stage M2 or M3. As of October 2015, 51 (58.6%) patients were alive and 31 (35.6%) had died. Five patients (5.7%) were lost to followup. Twenty-six patients relapsed. The median follow-up time was 58 months (range 4–187). Mean overall survival (OS) was 76.4% at 3 years, 66.2% at 5 years and 59.2% at 10 years. Mean disease-free survival (DFS) was 75.8% at 3 years, 62.8% at 5 years and 56.6% at 10 years. Mean OS of stage M0 patients was 86.4% at 3 years, 74% at 5 years and 63.1% at 10 years. The OS of stage M1, M2 and M3 patients combined was 48.9% at 3 years, 44.0% at 5 years and 37.7% at 10 years. Conclusion: In Serbia, a MIC, it is possible to achieve good treatment results in children with medulloblastoma using international treatment guidelines and recommendations, available resources and an experienced team of professionals dedicated to pediatric neurooncology. © 2018 Zerbinis Publications. All Rights Reserved.ChildrenMedulloblastomaSurvivalTreatment